Floatz Rating
C38/100
Confidence
Indicative
Sponsor
Madonna Magdy Fahmy
Modality
mixture
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05279586CT.gov Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatic Encephalopathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Colistin (this asset) | Madonna Magdy Fahmy | Early P1 | C · 38 |
| L-Ornithine L-Aspartate | Jinnah Postgraduate Medical Centre | P4 | BBB |
| Rifaximin | General Hospital of Shenyang Military Region | P4 | BBB |
| Lactulose | General Hospital of Shenyang Military Region | P4 | BBB |
| Normal Human Serum Albumin | General Hospital of Shenyang Military Region | P4 | BB |
| L-Ornithine-L-Aspartate | Qurratul Ain Jamil | P4 | BB |
| Lactose | Centro Regional para el Estudio de las Enfermedades Digestivas | P4 | BB |
| Ornithine | Imperial College London | P4 | BB |
| Blood, Whole | Imperial College London | P4 | BB |
+38 more in the Hepatic Encephalopathy cohort
Other indications for Colistin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cystic Fibrosis | — | P4 | BBB · 72 |
| Pseudomonas Aeruginosa Infectious Disease | — | P2 | B · 57 |
| Colorectal Cancer | — | P4 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Colistin in Hepatic Encephalopathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/colistin-hepatic-encephalopathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →